Clinical trials: Treatment-Resistant Major Depressive Disorder
Treatment Resistant Major Depressive Disorder
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD).
- Trial name
- STRIDE-1 (NCT02741791)
- Testing
- AXS-05, Bupropion
- Where
- 74 sites in United States
- Volunteers
- 312 people
- Sponsor
- Axsome Therapeutics, Inc.
Unipolar Depression, Treatment Resistant Depression
Home-administered tDCS for Treatment of Depression
This study will determine the safety and efficacy of home administered tDCS in adults with unipolar depression. The device used to administer tDCS will be the Soterix Medical 1X1 mini-CT.
- Trial name
- NCT04781127
- Testing
- Soterix Medical mini-CT tDCS stimulator
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Soterix Medical
Major Depression
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
Background: Drugs and talk therapy help treat depression, but these treatments usually take quite a bit of time to work. Ketamine is a fast-acting antidepressant, but it has side effects like unusual dreams and experiences.
- Trial name
- NCT02484456
- Testing
- AV 101 (4-Chlorokynurenine)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
The Antidepressant Advisor (Study 3): fMRI Study to Predict Treatment Response in Patients With Depression
This prospective observational study (ADeSS-Study3) investigates candidate biomarkers prospectively predicting response to antidepressant medications and prognosis in major depressive disorder (MDD).
- Trial name
- ADeSS_S3 (NCT04342299)
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- King's College London
Major Depressive Disorder, Treatment Resistant Depression
The Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression
Major Depressive Disorder (MDD) is a very common illness that is usually treated with antidepressant medication. Depression can be caused by many things such as childhood experiences, genetics, and changes in the way the body and…
- Trial name
- NCT06163625
- Testing
- Repetitive Transcranial Magnetic Stimulation, Research Interview, Questionnaires, Brain Scan
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Resistant Depression, Moods Disorders
tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients
The aim is to investigate the effect of transcranial Direct Current Stimulation (tDCS) applied at the anodal left CDLPF of patients with resistant depression compared to patients treated with conventional therapy.
- Conditions
- Resistant Depression, Moods Disorders, Unipolar Depression, Bipolar Disorder
- Trial name
- STICODEP (NCT01644747)
- Testing
- transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)
- Where
- 6 sites in France
- Volunteers
- 87 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Major Depressive Disorder, Treatment Resistant Depression
Maintenance rTMS for Depression (Maitr-De)
Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising intervention for treatment-resistant depression (TRD), yet substantial uncertainties persist regarding its efficacy as a maintenance treatment.
- Trial name
- Maitr-De (NCT06938841)
- Testing
- Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:
- Where
- 3 sites in United States, Australia
- Volunteers
- 75 people
- Sponsor
- University of California, San Diego
Treatment Resistant Major Depression Disorder
DBS of the Habenula for Treatment- Resistant Major Depression
The habenula(Hb) is an epithalamic structure located at the center of the dorsal diencephalic conduction system, a pathway involved in linking forebrain to midbrain regions.
- Trial name
- NCT03347487
- Testing
- Deep brain stimuation system implantation
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Ruijin Hospital
Depression, Unipolar Depression
Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression
This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for depression.
- Conditions
- Depression, Unipolar Depression, Treatment Resistant Depression
- Trial name
- CREST-MST (NCT03191058)
- Testing
- Magnetic Seizure Therapy, Electroconvulsive Therapy
- Where
- 3 sites in United States, Canada
- Volunteers
- 239 people
- Sponsor
- University of Texas Southwestern Medical Center
Depression, Bipolar Depression
Efficacy of Convulsive Therapies During Continuation
This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) and two different forms of electroconvulsive therapy (ECT) in sustaining response during and after a course of continuation treatment.
- Conditions
- Depression, Bipolar Depression, Unipolar Depression, Treatment Resistant Depression
- Trial name
- CORRECT-C (NCT03711019)
- Testing
- Magnetic Seizure Therapy (MST), RUL-UB ECT, Bitemporal ECT
- Where
- 3 sites in Canada
- Volunteers
- 106 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Anhedonia
Psilocybin for Treatment-Resistant Depression
The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.
- Conditions
- Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
- Trial name
- NCT06230757
- Testing
- Psilocybin 25mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Treatment Resistant Depression, Major Depressive Disorder (MDD)
Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression
The goal of this clinical trial is to see if combining ketamine with behavioral activation (BA) therapy to treat moderate to severe treatment-resistant depression improves depressive symptoms and general functioning more than…
- Trial name
- NCT07801703
- Testing
- Ketamine (0.5 mg/kg), Behavioural Activation Therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- The Royal's Institute of Mental Health Research
Treatment Resistant Depression
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that…
- Trial name
- NCT01920555
- Testing
- Ketamine
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression, Major Depressive Disorder
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression
- Trial name
- OPTIMUM (NCT02960763)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 5 sites in United States, Canada
- Volunteers
- 742 people
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- SAINT-TRD (NCT03240692)
- Testing
- Accelerated theta-burst stimulation treatment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Depression, Depressive Disorder
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
The purpose of this study is to compare the relative effectiveness of 20 and 60 minutes of Low-Field Magnetic Stimulation in relieving symptoms in patients with major depression who are treatment resistant.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
- Trial name
- NCT02452892
- Testing
- LFMS
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Tal Medical, Inc.
Depression - Major Depressive Disorder
Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin
About one in three people with major depression respond poorly to standard antidepressant treatments. This kind of depression is called treatment-resistant depression, and it can lead to long-term disability, financial…
- Trial name
- NCT07164755
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- King's College London
Treatment Resistant Depression
Neurofeedback for Treatment Resistant Depression
The purpose of this study is to determine the clinical efficacy of real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) training to increase the amygdala's response to positive autobiographical memories in…
- Trial name
- NCT03428828
- Testing
- Amygdala Neurofeedback, Parietal Neurofeedback
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Kymberly Young
Depressive Disorder, Depressive Disorder, Major
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
The purpose of this study is to evaluate the effectiveness and safety of risperidone to augment SSRI therapy in patients with treatment-resistant depression and to demonstrate the long-term maintenance effect of risperidone as…
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depression
- Trial name
- NCT00044681
- Testing
- risperidone
- Volunteers
- 258 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms)
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
DECIDE- Deep phenotyping for clinical inferring response in treatment resistant depression -Study Building upon the "Biobanking" initiative at the Max Planck Institute of Psychiatry, the present project aims to identify…
- Conditions
- Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms
- Trial name
- DECIDE (NCT06396312)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Max-Planck-Institute of Psychiatry